enasidenib mesylate · Bristol Myers Squibb · NDA 209606
Idhifa
Earliest generic entry, as listed · earliest of 2 marketed strengths
16 Sep 2034
Blocked by patent: US 9732062.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9732062 | substance | 16 Sep 2034 |
| US 10093654 | substance, product, use U-2087 | 1 Aug 2034 |
| US 9738625 | substance | 1 Aug 2034 |
| US 10294215 | product, use U-2087 | 7 Jan 2033 |
| US 9512107 | substance, product, use U-2087 | 7 Jan 2033 |
| US 10610125 | use U-2087 | 21 Jun 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 209606 · 001 · RLD | tablet, oral | EQ 50MG BASE | 16 Sep 2034 |
| 209606 · 002 · RLD | tablet, oral | EQ 100MG BASE | 16 Sep 2034 |